Giuliano Binetti

List of Publications by Year
in descending order

263	15,009	13865 67	28296 105
papers	citations	h-index	g-index

265	265	265	15721
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cerebrospinal Fluid EV Concentration and Size Are Altered in Alzheimerâ€™s Disease and Dementia with Lewy Bodies. Cells, 2022, 11, 462.	4.1	7
2	Plasma Small Extracellular Vesicles with Complement Alterations in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration. Cells, 2022, 11, 488.	4.1	7
3	tDCS-Induced Memory Reconsolidation Effects: Analysis of Prominent Predicting Factors. Frontiers in Neuroscience, 2022, 16, 814003.	2.8	4
4	Association of rs3027178 polymorphism in the circadian clock gene PER1 with susceptibility to Alzheimerâ€™s disease and longevity in an Italian population. GeroScience, 2022, 44, 881-896.	4.6	6
5	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
6	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
7	Plasma Extracellular Vesicle Size and Concentration Are Altered in Alzheimerâ€™s Disease, Dementia With Lewy Bodies, and Frontotemporal Dementia. Frontiers in Cell and Developmental Biology, 2021, 9, 667369.	3.7	18
8	Copper Imbalance in Alzheimerâ€™s Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating ATP7B Gene Variants. Biomolecules, 2021, 11, 960.	4.0	33
9	Cognitive Tele-Enhancement in Healthy Older Adults and Subjects With Subjective Memory Complaints: A Review. Frontiers in Neurology, 2021, 12, 650553.	2.4	2
10	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
11	Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimerâ€™s Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene. International Journal of Molecular Sciences, 2021, 22, 13633.	4.1	8
12	Effects of Transcranial Direct Current Stimulation on Episodic Memory in Amnestic Mild Cognitive Impairment: A Pilot Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2020, 75, 1403-1413.	3.9	33
13	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	3.1	35
14	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
15	Effectiveness of an Innovative Cognitive Treatment and Telerehabilitation on Subjects With Mild Cognitive Impairment: A Multicenter, Randomized, Active-Controlled Study. Frontiers in Aging Neuroscience, 2020, 12, 585988.	3.4	37
16	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
17	Polymorphic Genetic Markers of the GABA Catabolism Pathway in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 301-311.	2.6	5
18	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.1	7

#	Article	IF	Citations
19	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 77, 1129-1141.	2.6	55
20	Iron Serum Markers Profile in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 78, 1373-1380.	2.6	3
21	Diagnostic and prognostic value of serum NfL and p-Tau₁₈₁in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 960-967.	1.9	93
22	The Missing Heritability of Sporadic Frontotemporal Dementia: New Insights from Rare Variants in Neurodegenerative Candidate Genes. International Journal of Molecular Sciences, 2019, 20, 3903.	4.1	14
23	Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. Scientific Reports, 2019, 9, 10854.	3.3	9
24	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	4.2	33
25	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	1.9	19
26	A Novel Nonsense Angiogenin Mutation is Associated With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2019, 33, 163-165.	1.3	9
27	Incidence of frontotemporal lobar degeneration in Italy. Neurology, 2019, 92, e2355-e2363.	1.1	35
28	Novel <scp>CSF</scp> biomarkers in genetic frontotemporal dementia identified by proteomics. Annals of Clinical and Translational Neurology, 2019, 6, 698-707.	3.7	42
29	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	7.6	41
30	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47
31	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nature Medicine, 2019, 25, 152-164.	30.7	111
32	Cognitive telerehabilitation in mild cognitive impairment, Alzheimerâ€™s disease and frontotemporal dementia: A systematic review. Journal of Telemedicine and Telecare, 2019, 25, 67-79.	2.7	71
33	Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Annals of Clinical and Translational Neurology, 2018, 5, 583-597.	3.7	48
34	CXCR4 involvement in neurodegenerative diseases. Translational Psychiatry, 2018, 8, 73.	4.8	66
35	Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 61, 1477-1483.	2.6	15
36	Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 61, 1053-1060.	2.6	6

#	Article	IF	Citations
37	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
38	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	3.1	19
39	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	3.1	40
40	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	3.1	16
41	Copper dyshomeostasis in Wilson disease and Alzheimer's disease as shown by serum and urine copper indicators. Journal of Trace Elements in Medicine and Biology, 2018, 45, 181-188.	3.0	73
42	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
43	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	2.6	12
44	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	12.8	263
45	The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease. Alzheimer's Research and Therapy, 2018, 10, 94.	6.2	37
46	Rac1 activation links tau hyperphosphorylation and AÎ² dysmetabolism in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 61.	5.2	49
47	Serum Copper is not Altered in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 63, 1427-1432.	2.6	6
48	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Medicine, 2018, 15, e1002487.	8.4	111
49	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 152-164.	1.9	107
50	Effects of Multiple Genetic Loci on Age atÂOnset in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2017, 56, 1271-1278.	2.6	4
51	The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 825-833.	2.6	15
52	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	7.6	55
53	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimerâ€™s disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
54	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87

#	Article	IF	Citations
55	The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort. Journal of Alzheimer's Disease, 2017, 61, 753-760.	2.6	26
56	Strengthening of Existing Episodic Memories Through Non-invasive Stimulation of Prefrontal Cortex in Older Adults with Subjective Memory Complaints. Frontiers in Aging Neuroscience, 2017, 9, 401.	3.4	29
57	Loss of Neuroprotective Factors in Neurodegenerative Dementias: The End or the Starting Point?. Frontiers in Neuroscience, 2017, 11, 672.	2.8	26
58	PRNP P39L Variant is a Rare Cause ofÂFrontotemporal Dementia in Italian Population. Journal of Alzheimer's Disease, 2016, 50, 353-357.	2.6	15
59	Progranulin Mutations Affects Brain Oscillatory Activity in Fronto-Temporal Dementia. Frontiers in Aging Neuroscience, 2016, 8, 35.	3.4	8
60	Genetic Counseling and Testing for Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. Journal of Alzheimer's Disease, 2016, 51, 277-291.	2.6	18
61	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. Journal of Alzheimer's Disease, 2016, 55, 585-595.	2.6	41
62	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 213-224.	7.7	83
63	Loss of exosomes in progranulin-associated frontotemporal dementia. Neurobiology of Aging, 2016, 40, 41-49.	3.1	47
64	Rare Variants inPLD3Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	2.5	23
65	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	10.2	432
66	Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. Neurological Sciences, 2015, 36, 751-757.	1.9	9
67	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. Neurobiology of Aging, 2015, 36, 2904.e13-2904.e26.	3.1	48
68	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	3.1	34
69	Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Aging Neuroscience, 2014, 6, 179.	3.4	8
70	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy. Neuropsychiatric Disease and Treatment, 2014, 10, 1003.	2.2	12
71	Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease. Annals of Neurology, 2014, 75, 574-580.	5.3	93
72	Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism. Frontiers in Neurology, 2014, 5, 85.	2.4	12

#	Article	IF	Citations
73	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93
74	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
75	Pattern of structural and functional brain abnormalities in asymptomatic granulin mutation carriers. Alzheimer's and Dementia, 2014, 10, S354-S363.e1.	0.8	48
76	Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: A 24 months pilot observational open-label study. Neuropharmacology, 2014, 85, 284-289.	4.1	8
77	Electroencephalographic Upper/Low Alpha Frequency Power Ratio Relates to Cortex Thinning in Mild Cognitive Impairment. Neurodegenerative Diseases, 2014, 14, 18-30.	1.4	17
78	EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment.. Current Alzheimer Research, 2014, 11, 192-199.	1.4	7
79	Predictors of comprehensive stimulation program efficacy in patients with cognitive impairment. Clinical practice recommendations. International Journal of Geriatric Psychiatry, 2013, 28, 26-33.	2.7	19
80	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. Journal of Neurology, 2013, 260, 640-650.	3.6	50
81	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.8	51
82	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiology of Aging, 2013, 34, 1711.e7-1711.e13.	3.1	43
83	The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian caseâ€“control cohorts. Alzheimer's and Dementia, 2013, 9, 392-399.	0.8	40
84	C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology, 2013, 81, 1332-1341.	1.1	84
85	<scp>TMEM</scp>106B p.T185S regulates <scp>TMEM</scp>106B protein levels: implications for frontotemporal dementia. Journal of Neurochemistry, 2013, 126, 781-791.	3.9	87
86	Secretory Leukocyte Protease Inhibitor Protein Regulates the Penetrance of Frontotemporal Lobar Degeneration in Progranulin Mutation Carriers. Journal of Alzheimer's Disease, 2013, 38, 533-539.	2.6	10
87	EEG upper/low alpha frequency power ratio relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment. Frontiers in Aging Neuroscience, 2013, 5, 63.	3.4	44
88	Increase of theta frequency is associated with reduction in regional cerebral blood flow only in subjects with mild cognitive impairment with higher upper alpha/low alpha EEG frequency power ratio. Frontiers in Behavioral Neuroscience, 2013, 7, 188.	2.0	24
89	C9ORF72 Hexanucleotide Repeat Number in Frontotemporal Lobar Degeneration: A Genotype-Phenotype Correlation Study. Journal of Alzheimer's Disease, 2013, 38, 799-808.	2.6	43
90	Optimal Plasma Progranulin Cutoff Value for Predicting Null Progranulin Mutations in Neurodegenerative Diseases: A Multicenter Italian Study. Neurodegenerative Diseases, 2012, 9, 121-127.	1.4	88

#	Article	IF	Citations
91	Analysis of Grey Matter in Thalamus and Basal Ganglia Based on EEG Î±3/Î±2 Frequency Ratio Reveals Specific Changes in Subjects with Mild Cognitive Impairment. ASN Neuro, 2012, 4, AN20120058.	2.7	21
92	Genetics and Expression Analysis of the Specificity Protein 4 Gene (SP4) in Patients with Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2012, 31, 537-542.	2.6	9
93	Estimating the Age of the Most Common Italian GRN Mutation: Walking Back to Canossa Times. Journal of Alzheimer's Disease, 2012, 33, 69-76.	2.6	16
94	Distinct cerebrospinal fluid amyloidâ€beta peptide signatures in cognitive decline associated with <scp>A</scp>lzheimer's disease and schizophrenia. Electrophoresis, 2012, 33, 3738-3744.	2.4	34
95	Losing protein in the brain: The case of progranulin. Brain Research, 2012, 1476, 172-182.	2.2	23
96	EEG markers are associated to gray matter changes in thalamus and basal ganglia in subjects with mild cognitive impairment. NeuroImage, 2012, 60, 489-496.	4.2	48
97	Quantitative EEG Markers in Mild Cognitive Impairment: Degenerative versus Vascular Brain Impairment. International Journal of Alzheimer's Disease, 2012, 2012, 1-12.	2.0	44
98	Specific EEG Changes Associated with Atrophy of Hippocampus in Subjects with Mild Cognitive Impairment and Alzheimer's Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-8.	2.0	46
99	Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 30, 745-749.	2.6	35
100	An APOE Haplotype Associated with Decreased Îµ4 Expression Increases the Risk of Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 235-245.	2.6	58
101	Cerebrospinal Fluid Biomarkers for Alzheimerâ€™s Disease: The Present and the Future. Neurodegenerative Diseases, 2011, 8, 413-420.	1.4	40
102	MCI patientsâ€™ EEGs show group differences between those who progress and those who do not progress to AD. Neurobiology of Aging, 2011, 32, 563-571.	3.1	98
103	Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer's disease. Neurobiology of Aging, 2011, 32, 1231-1235.	3.1	56
104	Cystatin C is released in association with exosomes: A new tool of neuronal communication which is unbalanced in Alzheimer's disease. Neurobiology of Aging, 2011, 32, 1435-1442.	3.1	90
105	Role of OLR1 and Its Regulating hsa-miR369-3p in Alzheimer's Disease: Genetics and Expression Analysis. Journal of Alzheimer's Disease, 2011, 26, 787-793.	2.6	31
106	Volumetric Differences in Mapped Hippocampal Regions Correlate with Increase of High Alpha Rhythm in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	2.0	30
107	BAG1 is a Protective Factor for Sporadic Frontotemporal Lobar Degeneration but not for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 23, 701-707.	2.6	12
108	A Novel Progranulin Mutation Causing Frontotemporal Lobar Degeneration with Heterogeneous Phenotypic Expression. Journal of Alzheimer's Disease, 2011, 23, 7-12.	2.6	18

#	Article	IF	Citations
109	Anatomical Substrate and Scalp EEG Markers are Correlated in Subjects with Cognitive Impairment and Alzheimer's Disease. Frontiers in Psychiatry, 2011, 1, 152.	2.6	33
110	Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers. Journal of Alzheimer's Disease, 2011, 27, 781-790.	2.6	45
111	A Novel MAPT Mutation Associated with the Clinical Phenotype of Progressive Nonfluent Aphasia. Journal of Alzheimer's Disease, 2011, 26, 19-26.	2.6	28
112	Role of hnRNP-A1 and miR-590-3p in Neuronal Death: Genetics and Expression Analysis in Patients with Alzheimer Disease and Frontotemporal Lobar Degeneration. Rejuvenation Research, 2011, 14, 275-281.	1.8	57
113	Free Copper Distinguishes Mild Cognitive Impairment Subjects from Healthy Elderly Individuals. Journal of Alzheimer's Disease, 2011, 23, 239-248.	2.6	72
114	TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology, 2011, 76, 467-474.	1.1	211
115	A Window into the Heterogeneity of Human Cerebrospinal Fluid AÎ²Peptides. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	14
116	Preliminary Evidence of Validity of the Revised Criteria for Alzheimer Disease Diagnosis. Alzheimer Disease and Associated Disorders, 2010, 24, 108-114.	1.3	13
117	Failure to Replicate an Association of rs5984894 SNP in the PCDH11X Gene in a Collection of 1,222 Alzheimer's Disease Affected Patients. Journal of Alzheimer's Disease, 2010, 21, 385-388.	2.6	11
118	Plasma Cystatin C and Risk of Developing Alzheimer's Disease in Subjects with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 22, 985-991.	2.6	28
119	The new Alzheimerâ€™s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology, 2010, 257, 2004-2014.	3.6	44
120	Optimization protocol for amyloidâ€Î²2 peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics - Clinical Applications, 2010, 4, 352-357.	1.6	27
121	The CST3 B haplotype is associated with frontotemporal lobar degeneration. European Journal of Neurology, 2010, 17, 143-146.	3.3	14
122	GRN Variability Contributes to Sporadic Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2010, 19, 171-177.	2.6	28
123	The H1 Haplotype of the Tau Gene (MAPT) is Associated with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 19, 909-914.	2.6	20
124	FUS/TLS Genetic Variability in Sporadic Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2010, 19, 1317-1322.	2.6	6
125	EEG Markers Discriminate Among Different Subgroup of Patients With Mild Cognitive Impairment. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 58-73.	1.9	35
126	Progranulin Mutations are a Common Cause of FTLD in Northern Italy. Alzheimer Disease and Associated Disorders, 2010, 24, 308-309.	1.3	21

#	Article	IF	Citations
127	Evidence for Sub-Haplogroup H5 of Mitochondrial DNA as a Risk Factor for Late Onset Alzheimer's Disease. PLoS ONE, 2010, 5, e12037.	2.5	117
128	Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration?. Neuroscience Letters, 2010, 482, 240-244.	2.1	9
129	Is cognitive function linked to serum free copper levels? A cohort study in a normal population. Clinical Neurophysiology, 2010, 121, 502-507.	1.5	84
130	Effects of Donepezil, Galantamine and Rivastigmine in 938 Italian Patients with AlzheimerÊ¼s Disease. CNS Drugs, 2010, 24, 163-176.	5.9	44
131	Novel T719P AÎ²PP Mutation Unbalances the Relative Proportion of Amyloid-Î² Peptides. Journal of Alzheimer's Disease, 2009, 18, 295-303.	2.6	27
132	Longitudinal prognostic value of serum â€œfreeâ€•copper in patients with Alzheimer disease. Neurology, 2009, 72, 50-55.	1.1	129
133	Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiology of Disease, 2009, 33, 379-385.	4.4	107
134	Validation of Alzheimerâ€™s disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimerâ€™s Disease Neuroimaging Initiative (E-ADNI). Experimental Gerontology, 2009, 44, 579-585.	2.8	60
135	Regional atrophy of transcallosal prefrontal connections in cognitively normal APOE Ïµ4 carriers. Journal of Magnetic Resonance Imaging, 2009, 29, 1021-1026.	3.4	36
136	Implications of metal exposure and liver function in Parkinsonian patients resident in the vicinities of ferroalloy plants. Journal of Neural Transmission, 2009, 116, 1281-1287.	2.8	37
137	CCL8/MCP-2 association analysis in patients with Alzheimerâ€™s disease and frontotemporal lobar degeneration. Journal of Neurology, 2009, 256, 1379-1381.	3.6	7
138	HOXA1 A218G Polymorphism is Associated with Smaller Cerebellar Volume in Healthy Humans. Journal of Neuroimaging, 2009, 19, 353-358.	2.0	11
139	The NOS3 G894T (Glu298Asp) polymorphism is a risk factor for frontotemporal lobar degeneration. European Journal of Neurology, 2009, 16, 37-42.	3.3	22
140	DCUN1D1is a risk factor for frontotemporal lobar degeneration. European Journal of Neurology, 2009, 16, 870-873.	3.3	15
141	Directionality of EEG synchronization in Alzheimer's disease subjects. Neurobiology of Aging, 2009, 30, 93-102.	3.1	132
142	Late onset neurodegenerative diseases: A theoretical point of view. Medical Hypotheses, 2009, 72, 102.	1.5	1
143	Increase of theta/gamma ratio is associated with memory impairment. Clinical Neurophysiology, 2009, 120, 295-303.	1.5	87
144	The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clinical and Experimental Research, 2009, 21, 266-276.	2.9	31

#	Article	IF	Citations
145	Mapping the effect of APOE Îµ4 on gray matter loss in Alzheimer's disease in vivo. NeuroImage, 2009, 45, 1090-1098.	4.2	71
146	Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimer's and Dementia, 2009, 5, 307-317.	0.8	80
147	H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers. European Journal of Human Genetics, 2009, 17, 287-294.	2.8	11
148	Increasing Hippocampal Atrophy and Cerebrovascular Damage Is Differently Associated With Functional Cortical Coupling in MCI Patients. Alzheimer Disease and Associated Disorders, 2009, 23, 323-332.	1.3	23
149	Increase of Theta/Gamma and Alpha3/Alpha2 Ratio is Associated with Amygdalo-Hippocampal Complex Atrophy. Journal of Alzheimer's Disease, 2009, 17, 349-357.	2.6	56
150	MCP-1 A-2518G Polymorphism: Effect on Susceptibility for Frontotemporal Lobar Degeneration and on Cerebrospinal Fluid MCP-1 Levels. Journal of Alzheimer's Disease, 2009, 17, 125-133.	2.6	17
151	Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. Journal of Neural Transmission, 2008, 115, 1047-1050.	2.8	52
152	Exosomes: The Trojan horses of neurodegeneration. Medical Hypotheses, 2008, 70, 1226-1227.	1.5	65
153	Effect of the XbaI polymorphism of estrogen receptor alpha on postmenopausal gray matter. Neuroscience Letters, 2008, 434, 304-309.	2.1	8
154	A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiology of Aging, 2008, 29, 427-435.	3.1	109
155	Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology, 2008, 71, 1235-1239.	1.1	285
156	Association of Blood Pressure and Genetic Background With White Matter Lesions in Patients With Mild Cognitive Impairment. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 510-517.	3.6	8
157	Cerebrovascular Disease and Hippocampal Atrophy Are Differently Linked to Functional Coupling of Brain Areas: An EEG Coherence Study in MCI Subjects. Journal of Alzheimer's Disease, 2008, 14, 285-299.	2.6	57
158	Clinical and Neuropsychological Features Associated with Structural Imaging Patterns in Patients with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2007, 23, 175-183.	1.5	19
159	Presenilin 2 mutations alter cystatin C trafficking in mouse primary neurons. Neurobiology of Aging, 2007, 28, 371-376.	3.1	22
160	Homocysteine and electroencephalographic rhythms in Alzheimer disease: A multicentric study. Neuroscience, 2007, 145, 942-954.	2.3	34
161	Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimerâ€™s disease subjects. Clinical Neurophysiology, 2007, 118, 1244-1260.	1.5	58
162	Vascular damage and EEG markers in subjects with mild cognitive impairment. Clinical Neurophysiology, 2007, 118, 1866-1876.	1.5	66

#	Article	IF	Citations
163	Hippocampal atrophy and EEG markers in subjects with mild cognitive impairment. Clinical Neurophysiology, 2007, 118, 2716-2729.	1.5	78
164	Blockade of the Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Death Receptor DR5 Prevents Î²-Amyloid Neurotoxicity. Neuropsychopharmacology, 2007, 32, 872-880.	5.4	36
165	Resting EEG sources correlate with attentional span in mild cognitive impairment and Alzheimer's disease. European Journal of Neuroscience, 2007, 25, 3742-3757.	2.6	101
166	Dementia, delusions and seizures: storage disease or genetic AD?. European Journal of Neurology, 2007, 14, 1057-1059.	3.3	31
167	Presenilin 2 is secreted in mouse primary neurons: A release enhanced by apoptosis. Mechanisms of Ageing and Development, 2007, 128, 350-353.	4.6	6
168	Tau missing from CSF. Journal of Neurology, 2007, 254, 107-109.	3.6	5
169	Genotype (cystatin C) and EEG phenotype in Alzheimer disease and mild cognitive impairment: A multicentric study. NeuroImage, 2006, 29, 948-964.	4.2	76
170	Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study. Clinical Neurophysiology, 2006, 117, 252-268.	1.5	260
171	Frontal white matter volume and delta EEG sources negatively correlate in awake subjects with mild cognitive impairment and Alzheimer's disease. Clinical Neurophysiology, 2006, 117, 1113-1129.	1.5	150
172	Fronto-parietal coupling of brain rhythms in mild cognitive impairment: A multicentric EEG study. Brain Research Bulletin, 2006, 69, 63-73.	3.0	159
173	Effects of estrogens on cognition and brain morphology: Involvement of the cerebellum. Maturitas, 2006, 54, 222-228.	2.4	41
174	Conversion from mild cognitive impairment to Alzheimerâ€™s disease is predicted by sources and coherence of brain electroencephalography rhythms. Neuroscience, 2006, 143, 793-803.	2.3	242
175	Action and object naming in frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration.. Neuropsychology, 2006, 20, 558-565.	1.3	190
176	Effects of hormone therapy on brain morphology of healthy postmenopausal women. Menopause, 2006, 13, 584-591.	2.0	81
177	Areas of intervention for genetic counselling of dementia: Cross-cultural comparison between Italians and Americans. Patient Education and Counseling, 2006, 64, 285-293.	2.2	9
178	Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium, 2006, 39, 539-550.	2.4	136
179	The H2 MAPT haplotype is associated with familial frontotemporal dementia. Neurobiology of Disease, 2006, 22, 357-362.	4.4	31
180	Sources of cortical rhythms in adults during physiological aging: A multicentric EEG study. Human Brain Mapping, 2006, 27, 162-172.	3.6	253

#	Article	IF	Citations
181	Apolipoprotein E and alpha brain rhythms in mild cognitive impairment: A multicentric Electroencephalogram study. Annals of Neurology, 2006, 59, 323-334.	5.3	92
182	Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1219-1222.	1.9	92
183	The Heterogeneity and Natural History of Mild Cognitive Impairment. Archives of Neurology, 2005, 62, 163.	4.5	3
184	Circulating Levels of Soluble Receptor for Advanced Glycation End Products in Alzheimer Disease and Vascular Dementia. Archives of Neurology, 2005, 62, 1734.	4.5	195
185	Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. Experimental Cell Research, 2005, 308, 78-84.	2.6	34
186	Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. Neurobiology of Disease, 2005, 18, 638-648.	4.4	73
187	Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiology of Aging, 2005, 26, 455-464.	3.1	43
188	Lack of association between MnSOD gene polymorphism and sporadic Alzheimerâ€™s Disease. Aging Clinical and Experimental Research, 2005, 17, 445-448.	2.9	9
189	The practice of dementia care. , 2005, , 21-27.		0
190	Prevalence of Pathogenic Mutations in an Italian Clinical Series of Patients with Familial Dementia. Current Alzheimer Research, 2004, 1, 215-218.	1.4	15
191	Relation of Apolipoprotein(a) Size to Alzheimerâ€™s Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2004, 18, 189-196.	1.5	21
192	Frontotemporal dementia: impact of P301L tau mutation on a healthy carrier. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1607-1610.	1.9	27
193	Abnormal frontoâ€parietal coupling of brain rhythms in mild Alzheimer's disease: a multicentric EEG study. European Journal of Neuroscience, 2004, 19, 2583-2590.	2.6	137
194	?Immigrant paid caregivers? and primary caregivers' burden. International Journal of Geriatric Psychiatry, 2004, 19, 1103-1104.	2.7	9
195	The presenilin 2 M239I mutation associated with familial Alzheimer's disease reduces Ca2+ release from intracellular stores. Neurobiology of Disease, 2004, 15, 269-278.	4.4	80
196	Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. Neuroscience Letters, 2004, 356, 119-122.	2.1	49
197	Apolipoprotein(a) null phenotype is related to a delayed age at onset of Alzheimer's disease. Neuroscience Letters, 2004, 357, 45-48.	2.1	15
198	Possible association of mitochondrial transcription factor A (TFAM) genotype with sporadic Alzheimer disease. Neuroscience Letters, 2004, 369, 219-223.	2.1	47

#	Article	IF	Citations
199	Cortical alpha rhythms in mild Alzheimer's disease. A multicentric EEG study. International Congress Series, 2004, 1270, 44-49.	0.2	3
200	Individual analysis of EEG frequency and band power in mild Alzheimer's disease. Clinical Neurophysiology, 2004, 115, 299-308.	1.5	311
201	Mapping distributed sources of cortical rhythms in mild Alzheimer's disease. A multicentric EEG study. NeuroImage, 2004, 22, 57-67.	4.2	253
202	Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2. Neurogenetics, 2003, 4, 213-217.	1.4	61
203	Inhibition of energy metabolism down-regulates the Alzheimer related presenilin 2 gene. Journal of Neural Transmission, 2003, 110, 1029-1039.	2.8	10
204	Atypical dementia associated with a novel presenilinâ€2 mutation. Annals of Neurology, 2003, 54, 832-836.	5.3	51
205	Association between small apolipoprotein(a) isoforms and frontotemporal dementia in humans. Neuroscience Letters, 2003, 353, 201-204.	2.1	12
206	BACE-2 is overexpressed in Downâ€™s syndrome. Experimental Neurology, 2003, 182, 335-345.	4.1	45
207	Prevalence of TAU mutations in an Italian clinical series of familial frontotemporal patients. Neuroscience Letters, 2003, 338, 85-87.	2.1	35
208	Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiology of Disease, 2003, 13, 15-21.	4.4	59
209	An electronic memory aid to support prospective memory in patients in the early stages of Alzheimer's disease: A pilot study. Aging and Mental Health, 2003, 7, 22-27.	2.8	77
210	Increased Brain Î²-Amyloid Load, Phosphorylated Tau, and Risk of Alzheimer Disease Associated With an Intronic CYP46 Polymorphism. Archives of Neurology, 2003, 60, 29.	4.5	210
211	Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Molecular Psychiatry, 2002, 7, 136-137.	7.9	223
212	A Transcultural Study of Agitation in Dementia. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 171-174.	2.3	13
213	Predictors of cognitive improvement after reality orientation in Alzheimer's disease. Age and Ageing, 2002, 31, 193-196.	1.6	28
214	No association between DCP1 genotype and lateâ€onset Alzheimer disease. American Journal of Medical Genetics Part A, 2002, 114, 440-445.	2.4	23
215	Radial width of the temporal horn: a sensitive measure in Alzheimer disease. American Journal of Neuroradiology, 2002, 23, 35-47.	2.4	73
216	Non-replication of association between cathepsin D genotype and late onset Alzheimer disease. American Journal of Medical Genetics Part A, 2001, 105, 179-182.	2.4	25

#	Article	IF	Citations
217	Detection of the Presenilin 1 COOH-Terminal Fragment in the Extracellular Compartment: A Release Enhanced by Apoptosis. Experimental Cell Research, 2001, 269, 256-265.	2.6	10
218	Analysis of Alpha-2-Macroglobulin-2 Allele as a Risk Factor in Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2001, 12, 305-308.	1.5	10
219	A brief neuropsychological assessment for the differential diagnosis between frontotemporal dementia and Alzheimer's disease. European Journal of Neurology, 2001, 8, 125-132.	3.3	56
220	Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology, 2000, 54, 2006-2008.	1.1	60
221	Differences Between Pick Disease and Alzheimer Disease in Clinical Appearance and Rate of Cognitive Decline. Archives of Neurology, 2000, 57, 225.	4.5	86
222	No evidence for the involvement of interleukin 2 or the immunoglobulin heavy chain gene cluster in determining genetic susceptibility to multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 679-679.	1.9	14
223	Temporal lobe asymmetry in patients with Alzheimer's disease with delusions. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 187-191.	1.9	63
224	Pop music and frontotemporal dementia. Neurology, 2000, 55, 1935-1936.	1.1	34
225	High Prevalence of Pathogenic Mutations in Patients with Early-Onset Dementia Detected by Sequence Analyses of Four Different Genes. American Journal of Human Genetics, 2000, 66, 110-117.	6.2	178
226	Genetic Testing Should Not Be Advocated as a Diagnostic Tool in Familial Forms of Dementia. American Journal of Human Genetics, 2000, 67, 1033-1035.	6.2	15
227	Reply to Croes et al.. American Journal of Human Genetics, 2000, 67, 1035-1036.	6.2	3
228	High Frequency of Mutations in Four Different Disease Genes in Earlyâ€Onset Dementia. Annals of the New York Academy of Sciences, 2000, 920, 100-106.	3.8	24
229	Behavioral Syndromes in Alzheimerâ€™s Disease: Description and Correlates. Dementia and Geriatric Cognitive Disorders, 1999, 10, 130-138.	1.5	230
230	Presenilin 1 Protein Directly Interacts with Bcl-2. Journal of Biological Chemistry, 1999, 274, 30764-30769.	3.4	67
231	Modulation of Presenilin-1 Processing by Nitric Oxide during Apoptosis Induced by Serum Withdrawal and Glucose Deprivation. Annals of the New York Academy of Sciences, 1999, 893, 294-297.	3.8	2
232	Energy metabolism inhibition impairs amyloid precursor protein secretion from Alzheimer's fibroblasts. Neuroscience Letters, 1999, 263, 197-200.	2.1	29
233	Risperidone Treatment of Behavioral Disturbances in Outpatients With Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 336-342.	1.8	29
234	Provisional clinical and neuroradiological criteria for the diagnosis of Pick's disease. European Journal of Neurology, 1998, 5, 519-520.	3.3	23

#	Article	IF	Citations
235	Specific role for protein kinase CÎ± in the constitutive and regulated secretion of amyloid precursor protein in human skin fibroblasts. Neuroscience Letters, 1998, 240, 97-101.	2.1	54
236	Visual and spatial perception in the early phase of Alzheimer's disease.. Neuropsychology, 1998, 12, 29-33.	1.3	69
237			

#	Article	IF	Citations
253	Delusions and dementia: clinical and CT correlates. Acta Neurologica Scandinavica, 1995, 91, 271-275.	2.1	39
254	Evaluation of an italian educational programme for dementia caregivers: Results of a small-scale pilot study. International Journal of Geriatric Psychiatry, 1995, 10, 569-573.	2.7	8
255	Computed Tomography in the Detection of the Vascular Component in Dementia. Gerontology, 1995, 41, 121-128.	2.8	30
256	Semantic memory in alzheimer's disease: An analysis of category fluency. Journal of Clinical and Experimental Neuropsychology, 1995, 17, 82-89.	1.3	63
257	Defective phorbol ester-stimulated secretion of Î²-amyloid precursor protein from Alzheimer's disease fibroblasts. Neuroscience Letters, 1995, 201, 1-4.	2.1	60
258	Release from proactive interference in early Alzheimer's disease. Neuropsychologia, 1995, 33, 379-384.	1.6	16
259	Prosthetic bonds. International Journal of Geriatric Psychiatry, 1994, 9, 1005-1009.	2.7	0
260	Characterization and Distribution of Protein Kinase C Isoforms in Human Skin Fibroblasts. Archives of Biochemistry and Biophysics, 1994, 314, 107-111.	3.0	31
261	Neuropsychological Heterogeneity in Mild Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1993, 4, 321-326.	1.5	26
262	Delusions in Alzheimer's disease and multi-infarct dementia. Acta Neurologica Scandinavica, 1993, 88, 5-9.	2.1	61
263	Are the drugs prescribed to the el derly too many or not?. Pharmacological Research Communications, 1988, 20, 332.	0.2	0